A Phase 3 interventional study of Pegcetacoplan and Soliris in Paroxysmal Nocturnal Hemoglobinuria, sponsored by Apellis Pharmaceuticals, Inc.. Completed at 53 sites in 11 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-03-25.
Sponsored by Apellis Pharmaceuticals, Inc. (part of Biogen) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 68 studies in Hemoglobinuria, Paroxysmal with a site in United States — 10 open to participants now, 16 under way, 4 of them phase 3. Hemoglobinuria, Paroxysmal · United States.
Among the 68 studies in Hemoglobinuria, Paroxysmal with a site in United States, this one is the 15th largest by enrollment of the 54 interventional ones that give a count, is one of 4 that started in 2018, is one of 22 in phase 3, and was the 45th registered.
191 studies on the registry are indexed under Hemoglobinuria, Paroxysmal; 49 are open to participants now.
Browse Hemoglobinuria, Paroxysmal studies →10 of the 68 studies in Hemoglobinuria, Paroxysmal with a site in United States are open now. Recruiting first, the newest first:
Novartis Pharmaceuticals · Sites in United States, Brazil, Colombia and 3 more countries
Ages 2–18
Alexion Pharmaceuticals, Inc. · Sites in United States, Australia, France and 4 more countries
Women only
Novartis Pharmaceuticals · Sites in United States
Ages 18–99
Masonic Cancer Center, University of Minnesota · Sites in United States
Ages 0–75
International PNH Interest Group · Sites in United States
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 30 Hemoglobinuria, Paroxysmal studies recruiting now, 14 (47%) set no upper age limit and 12 (40%) stop at 75 or younger; 12 take children under 18; 4 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
68 studies; the count open now beside each. This study's row is marked.
First in 1996; this study’s year is marked. 4 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 80 is above the median of 33 across 150 interventional studies indexed under Hemoglobinuria, Paroxysmal.
Median enrollment 53 across the 54 interventional studies, 75 across the 13 observational. Of the 50 that completed or were terminated, 26 (52%) have results posted.
This tab as a report to print or save as PDF → With an account.
35 of 68 have an industry lead sponsor. The 10 most frequent:
This study is registered under Apellis Pharmaceuticals, Inc., one of the names counted as Biogen. Under that name alone:
Apellis Pharmaceuticals, Inc. is the lead sponsor of 28 studies on the registry; 3 are open to participants now.
Of its 18 completed or terminated interventional studies of FDA-regulated products, 16 (89%) have results posted.
Biogen has 6 studies filed under Hemoglobinuria, Paroxysmal — fewer than ten, so there is no comparison to draw.
3 of the studies in Hemoglobinuria, Paroxysmal with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04432584Phase 3Hoffmann-La RocheA Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Crovalimab Versus Eculizumab in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With Complement Inhibitors | 2027-04-18 |
| NCT04747613Phase 3Novartis PharmaceuticalsLong-term Safety and Tolerability of Iptacopan in Patients With Paroxysmal Nocturnal Hemoglobinuria | 2027-10-18 |
| NCT03520647National Heart, Lung, and Blood Institute (NHLBI)Haplo-identical Transplantation for Severe Aplastic Anemia, Hypo-plastic MDS and PNH Using Peripheral Blood Stem Cells and Post-transplant Cyclophosphamide for GVHD Prophylaxis | 2027-06-01 |
Add all 3 to your calendar (.ics) → With an account.
Among the 68 studies in Hemoglobinuria, Paroxysmal with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Evaluation of the Efficacy and Safety of APL-2 in Patients with Paroxysmal Nocturnal Hemoglobinuria
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
This study includes cardiac safety evaluations. The following cardiac eligibility criteria are necessary to avoid confounding the cardiac safety outcomes:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
1080 mg pegcetacoplan administered subcutaneously twice-weekly or every three days.
Drug: Pegcetacoplan · Drug: Soliris
Complement (C5) Inhibitor.
Drug: Pegcetacoplan · Drug: Soliris
Complement (C3) Inhibitor
Also known as: APL-2
Complement (C5) Inhibitor
Least Squares (LS) Mean Change From Baseline to Week 16 in Hemoglobin (Hb) Level During the RCP
Baseline was the average of measurements recorded before taking the first dose of pegcetacoplan, which included local and central laboratory values during the screening period. Analysis excluded data before the RCP and was censored for transfusions.
Time frame: Baseline and Week 16
Percentage of Subjects Who Did Not Require a Transfusion (Transfusion Avoidance) During the RCP
Subjects who experienced more than 1 transfusion during the RCP are only counted once. Subjects who did not have a transfusion but withdrew before Week 16 were considered as having a transfusion in the analysis of transfusion avoidance.
Time frame: Day 1 to Week 16
LS Mean Change From Baseline to Week 16 in Absolute Reticulocyte Count (ARC) During the RCP
Baseline was the average of available measurements recorded from central laboratory before taking the first dose of pegcetacoplan. Analysis excluded data before the RCP and was censored for transfusions.
Time frame: Baseline and Week 16
LS Mean Change From Baseline to Week 16 in Lactate Dehydrogenase (LDH) Level During the RCP
Baseline was the average of available measurements recorded from central laboratory before taking the first dose of pegcetacoplan. Analysis excluded data before the RCP and was censored for transfusions.
Time frame: Baseline and Week 16
LS Mean Change From Baseline to Week 16 in Functional Assessment of Chronic Illness Therapy (FACIT) - Fatigue Scale Score During the RCP
The FACIT-fatigue scale version 4 is a 13-item Likert scaled instrument where the subject was presented with 13 statements and asked to indicate their response as it applied to the past 7 days. The 5 possible responses were 'Not at all' (0), 'A little bit (1), 'Somewhat' (2), 'Quite a bit' (3) and 'Very much' (4). With 13 statements the total score had a range of 0 to 52. A higher score corresponds to a higher quality of life (QoL). Baseline was the last available, nonmissing observation before taking the first dose of pegcetacoplan. Data collected after transfusion is excluded from analysis.
Time frame: Baseline and Week 16
Percentage of Subjects Who Achieved a Hb Response in the Absence of Transfusions at Week 16
Hb response was defined as an increase of at least 1 g/dL in Hb from Baseline at Week 16. Baseline was the average of measurements recorded before taking the first dose of pegcetacoplan, which included local and central laboratory values during the screening period. Analysis excluded data before the RCP and was censored for transfusions.
Time frame: Baseline and Week 16
Percentage of Subjects Who Achieved Reticulocyte Normalization in the Absence of Transfusions at Week 16
Reticulocyte normalization was defined as the ARC being below the upper limit of the gender-specific normal range at Week 16, censored for transfusions. Subjects who received a transfusion between Day 1 and Week 16 or withdrew without providing efficacy data at Week 16 were classified as nonresponders.
Time frame: Week 16
Percentage of Subjects Who Achieved Hb Normalization in the Absence of Transfusions at Week 16
Hb normalization was defined as the Hb level being above the lower limit of the normal range at Week 16, censored for transfusions. Subjects who received a transfusion between Day 1 and Week 16 or withdrew without providing efficacy data at Week 16 are classified as nonnormalization.
Time frame: Week 16
LS Mean Change From Baseline to Week 16 in Indirect Bilirubin Level During the RCP
Baseline was the average of available measurements recorded from central laboratory before taking the first dose of pegcetacoplan. Analysis excluded data before the RCP and was censored for transfusions.
Time frame: Baseline and Week 16
LS Mean Change From Baseline to Week 16 in Haptoglobin Level During the RCP
Baseline was the average of available measurements recorded from central laboratory before taking the first dose of pegcetacoplan. Analysis excluded data before the RCP and was censored for transfusions.
Time frame: Baseline and Week 16
LS Mean Change From Baseline to Week 16 in Linear Analog Scale Assessment (LASA) Scores During the RCP
The LASA consists of 3 items, where the respondents were asked to rate their perceived level of functioning. Specific domains included activity level, ability to carry out daily activities, and an item for overall QoL. Their level of functioning was reported on a 0 to 100 scale with 0 indicates "As low as could be" and 100 indicates "As high as could be". The combined score ranged from 0 to 300, with higher scores corresponding to a higher QoL.
Time frame: Baseline and Week 16
LS Mean Change From Baseline to Week 16 in European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire - Core 30 Scale (QLQ-C30) Scores During the RCP
The EORTC QLQ-C30 questionnaire (version 3.0) consists of 30 questions comprised of both multi-item scales and single-item measures to assess overall QoL in subjects. Questions are designated by functional scales, symptom scales, and global subject QoL/overall perceived health status. For the first 28 questions the 4 possible responses are "Not at all' (1), 'A little' (2), 'Quite a bit' (3) and 'Very much' (4). For the remaining 2 questions the response is requested on a 7-point scale from 1 ('Very poor') to 7 ('Excellent'). The raw scale scores were linear transformed, producing scale scores that ranged from 0% to 100%. A high scale score represents a higher response level. Hence for the functional scales and the global health status a higher score indicates a better QoL, whilst for the symptom scale scores this is implied by a lower score.
Time frame: Baseline and Week 16
Total Number of PRBC Units Transfused During the RCP
Subjects who withdrew during the RCP before Week 16 will have their number of units of PRBC estimated from the duration they were in the study.
Time frame: Day 1 to Week 16
Mean Change From Baseline to Week 48 in Hb Level During the Treatment Period
Baseline was the average of measurements recorded before taking the first dose of pegcetacoplan, which included local and central laboratory values during the screening period. Analysis excluded data before the RCP and was censored for transfusions.
Time frame: Baseline and Week 48
Mean Change From Week 17 to Week 48 in Hb Level During the Open-label Period
Baseline was the average of measurements recorded before taking the first dose of pegcetacoplan, which included local and central laboratory values during the screening period. Analysis excluded data before the RCP and was censored for transfusions.
Time frame: Week 17 and Week 48
Mean Change From Baseline to Week 48 in ARC During the Treatment Period
Baseline was the average of available measurements recorded from central laboratory before taking the first dose of pegcetacoplan. Analysis excluded data before the RCP and was censored for transfusions.
Time frame: Baseline and Week 48
Mean Change From Week 17 to Week 48 in ARC During the Open-label Period
Baseline was the average of available measurements recorded from central laboratory before taking the first dose of pegcetacoplan. Analysis excluded data before the RCP and was censored for transfusions.
Time frame: Week 17 and Week 48
Mean Change From Baseline to Week 48 in LDH Level During the Treatment Period
Baseline was the average of available measurements recorded from central laboratory before taking the first dose of pegcetacoplan. Analysis excluded data before the RCP and was censored for transfusions.
Time frame: Baseline and Week 48
Mean Change From Week 17 to Week 48 in LDH Level During the Open-label Period
Baseline was the average of available measurements recorded from central laboratory before taking the first dose of pegcetacoplan. Analysis excluded data before the RCP and was censored for transfusions.
Time frame: Week 17 and Week 48
Mean Change From Baseline to Week 48 in FACIT-Fatigue Scale Score During the Treatment Period
The FACIT-fatigue scale version 4 is a 13-item Likert scaled instrument where the subject was presented with 13 statements and asked to indicate their response as it applied to the past 7 days. The 5 possible responses were 'Not at all' (0), 'A little bit (1), 'Somewhat' (2), 'Quite a bit' (3) and 'Very much' (4). With 13 statements the total score had a range of 0 to 52. A higher score corresponds to a higher QoL. Baseline was the last available, nonmissing observation before taking the first dose of pegcetacoplan. Data collected after transfusion is excluded from analysis.
Time frame: Baseline and Week 48
Mean Change From Week 17 to Week 48 in FACIT-Fatigue Scale Score During the Open-label Period
The FACIT-fatigue scale is a 13 item Likert scaled instrument where the subject was presented with 13 statements and asked to indicate their response as it applied to the past 7 days. The 5 possible responses were 'Not at all' (0), 'A little bit (1), 'Somewhat' (2), 'Quite a bit' (3) and 'Very much' (4). With 13 statements the total score had a range of 0 to 52. Higher score corresponds to a higher QoL.
Time frame: Week 17 and Week 48
Mean Change From Baseline to Week 48 in LASA Scores During the Treatment Period
The LASA consists of 3 items, where the respondents were asked to rate their perceived level of functioning. Specific domains included activity level, ability to carry out daily activities, and an item for overall QoL. Their level of functioning was reported on a 0 to 100 scale with 0 indicates "As low as could be" and 100 indicates "As high as could be". The combined score ranged from 0 to 300, with higher scores corresponding to a higher QoL.
Time frame: Baseline and Week 48
Mean Change From Week 17 to Week 48 in LASA Scores During the Open-label Period
The FACIT-fatigue scale is a 13 item Likert scaled instrument where the subject was presented with 13 statements and asked to indicate their response as it applied to the past 7 days. The 5 possible responses were 'Not at all' (0), 'A little bit (1), 'Somewhat' (2), 'Quite a bit' (3) and 'Very much' (4). With 13 statements the total score had a range of 0 to 52. Higher score corresponds to a higher QoL.
Time frame: Week 17 and Week 48
Mean Change From Baseline to Week 48 in QLQ-C30 Scores During the Treatment Period
The EORTC QLQ-C30 questionnaire (version 3.0) consists of 30 questions comprised of both multi-item scales and single-item measures to assess overall QoL in subjects. Questions are designated by functional scales, symptom scales, and global subject QoL/overall perceived health status. For the first 28 questions the 4 possible responses are 'Not at all' (1), 'A little' (2), 'Quite a bit' (3) and 'Very much' (4). For the remaining 2 questions the response is requested on a 7-point scale from 1 ('Very poor') to 7 ('Excellent'). The raw scale scores were linear transformed, producing scale scores that ranged from 0% to 100%. A high scale score represents a higher response level. Hence for the functional scales and the global health status a higher score indicates a better QoL, whilst for the symptom scale scores this is implied by a lower score.
Time frame: Baseline and Week 48
Mean Change From Week 17 to Week 48 in QLQ-C30 Scores During the Open-label Period
The EORTC QLQ-C30 questionnaire (version 3.0) consists of 30 questions comprised of both multi-item scales and single-item measures to assess overall QoL in subjects. Questions are designated by functional scales, symptom scales, and global subject QoL/overall perceived health status. For the first 28 questions the 4 possible responses are 'Not at all' (1), 'A little' (2), 'Quite a bit' (3) and 'Very much' (4). For the remaining 2 questions the response is requested on a 7-point scale from 1 ('Very poor') to 7 ('Excellent'). The raw scale scores were linear transformed, producing scale scores that ranged from 0% to 100%. A high scale score represents a higher response level. Hence for the functional scales and the global health status a higher score indicates a better QoL, whilst for the symptom scale scores this is implied by a lower score.
Time frame: Week 17 and Week 48
Total Number of PRBC Units Transfused During the Open-Label Period
Number of units of PRBC transfused to subjects in the open-label period are reported.
Time frame: Week 17 to Week 48
This Phase 3, randomized, multicenter, open-label, active-comparator controlled study evaluated the efficacy and safety of pegcetacoplan (APL-2) in subjects with paroxysmal nocturnal hemoglobinuria who had received treatment with eculizumab (Soliris®) in the past.
| Milestone | Pegcetacoplan to Pegcetacoplan | Eculizumab to Pegcetacoplan |
|---|---|---|
| Started | 41 | 39 |
| Completed | 41 | 39 |
| Not completed | 0 | 0 |
| Milestone | Pegcetacoplan to Pegcetacoplan | Eculizumab to Pegcetacoplan |
|---|---|---|
| Started | 41 | 39 |
| Completed | 38 | 39 |
| Not completed | 3 | 0 |
| Withdrew: Adverse event | 3 | 0 |
| Milestone | Pegcetacoplan to Pegcetacoplan | Eculizumab to Pegcetacoplan |
|---|---|---|
| Started | 38 | 39 |
| Completed | 35 | 32 |
| Not completed | 3 | 7 |
| Withdrew: Adverse event | 3 | 7 |
Baseline was the average of measurements recorded before taking the first dose of pegcetacoplan, which included local and central laboratory values during the screening period. Analysis excluded data before the RCP and was censored for transfusions.
| Grams per deciliter (g/dL) | Pegcetacoplan to Pegcetacoplan | Eculizumab to Pegcetacoplan |
|---|---|---|
| Least Squares (LS) Mean Change From Baseline to Week 16 in Hemoglobin (Hb) Level During the RCP | 2.37 ± 0.363 | -1.47 ± 0.666 |
Subjects who experienced more than 1 transfusion during the RCP are only counted once. Subjects who did not have a transfusion but withdrew before Week 16 were considered as having a transfusion in the analysis of transfusion avoidance.
| Percentage of subjects | Pegcetacoplan to Pegcetacoplan | Eculizumab to Pegcetacoplan |
|---|---|---|
| Percentage of Subjects Who Did Not Require a Transfusion (Transfusion Avoidance) During the RCP | 85.4 | 15.4 |
Baseline was the average of available measurements recorded from central laboratory before taking the first dose of pegcetacoplan. Analysis excluded data before the RCP and was censored for transfusions.
| 10^9 cells/ liter (L) | Pegcetacoplan to Pegcetacoplan | Eculizumab to Pegcetacoplan |
|---|---|---|
| LS Mean Change From Baseline to Week 16 in Absolute Reticulocyte Count (ARC) During the RCP | -135.82 ± 6.543 | 27.79 ± 11.859 |
Baseline was the average of available measurements recorded from central laboratory before taking the first dose of pegcetacoplan. Analysis excluded data before the RCP and was censored for transfusions.
| Units (U)/L | Pegcetacoplan to Pegcetacoplan | Eculizumab to Pegcetacoplan |
|---|---|---|
| LS Mean Change From Baseline to Week 16 in Lactate Dehydrogenase (LDH) Level During the RCP | -14.76 ± 42.708 | -10.12 ± 71.025 |
The FACIT-fatigue scale version 4 is a 13-item Likert scaled instrument where the subject was presented with 13 statements and asked to indicate their response as it applied to the past 7 days. The 5 possible responses were 'Not at all' (0), 'A little bit (1), 'Somewhat' (2), 'Quite a bit' (3) and 'Very much' (4). With 13 statements the total score had a range of 0 to 52. A higher score corresponds to a higher quality of life (QoL). Baseline was the last available, nonmissing observation before taking the first dose of pegcetacoplan. Data collected after transfusion is excluded from analysis.
| Score on a scale | Pegcetacoplan to Pegcetacoplan | Eculizumab to Pegcetacoplan |
|---|---|---|
| LS Mean Change From Baseline to Week 16 in Functional Assessment of Chronic Illness Therapy (FACIT) - Fatigue Scale Score During the RCP | 9.22 ± 1.607 | -2.65 ± 2.821 |
Hb response was defined as an increase of at least 1 g/dL in Hb from Baseline at Week 16. Baseline was the average of measurements recorded before taking the first dose of pegcetacoplan, which included local and central laboratory values during the screening period. Analysis excluded data before the RCP and was censored for transfusions.
| Percentage of subjects | Pegcetacoplan to Pegcetacoplan | Eculizumab to Pegcetacoplan |
|---|---|---|
| Percentage of Subjects Who Achieved a Hb Response in the Absence of Transfusions at Week 16 | 75.6 | 0.0 |
Reticulocyte normalization was defined as the ARC being below the upper limit of the gender-specific normal range at Week 16, censored for transfusions. Subjects who received a transfusion between Day 1 and Week 16 or withdrew without providing efficacy data at Week 16 were classified as nonresponders.
| Percentage of subjects | Pegcetacoplan to Pegcetacoplan | Eculizumab to Pegcetacoplan |
|---|---|---|
| Percentage of Subjects Who Achieved Reticulocyte Normalization in the Absence of Transfusions at Week 16 | 78.0 | 2.6 |
Hb normalization was defined as the Hb level being above the lower limit of the normal range at Week 16, censored for transfusions. Subjects who received a transfusion between Day 1 and Week 16 or withdrew without providing efficacy data at Week 16 are classified as nonnormalization.
| Percentage of subjects | Pegcetacoplan to Pegcetacoplan | Eculizumab to Pegcetacoplan |
|---|---|---|
| Percentage of Subjects Who Achieved Hb Normalization in the Absence of Transfusions at Week 16 | 34.1 | 0.0 |
Baseline was the average of available measurements recorded from central laboratory before taking the first dose of pegcetacoplan. Analysis excluded data before the RCP and was censored for transfusions.
| Micromole (μmol)/L | Pegcetacoplan to Pegcetacoplan | Eculizumab to Pegcetacoplan |
|---|---|---|
| LS Mean Change From Baseline to Week 16 in Indirect Bilirubin Level During the RCP | -17.78 ± 2.727 | 4.15 ± 4.477 |
Baseline was the average of available measurements recorded from central laboratory before taking the first dose of pegcetacoplan. Analysis excluded data before the RCP and was censored for transfusions.
| g/L | Pegcetacoplan to Pegcetacoplan | Eculizumab to Pegcetacoplan |
|---|---|---|
| LS Mean Change From Baseline to Week 16 in Haptoglobin Level During the RCP | -0.02 ± 0.033 | 0.12 ± 0.063 |
The LASA consists of 3 items, where the respondents were asked to rate their perceived level of functioning. Specific domains included activity level, ability to carry out daily activities, and an item for overall QoL. Their level of functioning was reported on a 0 to 100 scale with 0 indicates "As low as could be" and 100 indicates "As high as could be". The combined score ranged from 0 to 300, with higher scores corresponding to a higher QoL.
| Score on a scale | Pegcetacoplan to Pegcetacoplan | Eculizumab to Pegcetacoplan |
|---|---|---|
| LS Mean Change From Baseline to Week 16 in Linear Analog Scale Assessment (LASA) Scores During the RCP | 49.38 ± 10.189 | -9.72 ± 18.988 |
The EORTC QLQ-C30 questionnaire (version 3.0) consists of 30 questions comprised of both multi-item scales and single-item measures to assess overall QoL in subjects. Questions are designated by functional scales, symptom scales, and global subject QoL/overall perceived health status. For the first 28 questions the 4 possible responses are "Not at all' (1), 'A little' (2), 'Quite a bit' (3) and 'Very much' (4). For the remaining 2 questions the response is requested on a 7-point scale from 1 ('Very poor') to 7 ('Excellent'). The raw scale scores were linear transformed, producing scale scores that ranged from 0% to 100%. A high scale score represents a higher response level. Hence for the functional scales and the global health status a higher score indicates a better QoL, whilst for the symptom scale scores this is implied by a lower score.
| Score on a scale | Pegcetacoplan to Pegcetacoplan | Eculizumab to Pegcetacoplan |
|---|---|---|
| Global Health Status/QoL | 15.91 ± 3.635 | -2.71 ± 8.515 |
| Functional Scales - Physical functioning | 16.92 ± 2.081 | 4.06 ± 3.605 |
| Functional Scales - Role functioning | 15.39 ± 3.930 | -9.04 ± 6.954 |
| Functional Scales - Emotional functioning | 7.98 ± 3.366 | 3.86 ± 7.237 |
| Functional Scales - Cognitive functioning | 5.76 ± 3.258 | -3.80 ± 6.420 |
| Functional Scales - Social functioning | 15.08 ± 2.946 | 3.82 ± 6.349 |
| Symptom Scales - Fatigue | -22.93 ± 3.321 | -2.18 ± 6.644 |
| Symptom Scales - Nausea and vomiting | -0.34 ± 1.632 | -0.33 ± 3.876 |
| Symptom Scales - Pain | -0.74 ± 4.323 | 2.01 ± 7.841 |
| Symptom Scales - Dyspnoea | -20.12 ± 3.488 | -5.55 ± 7.019 |
| Symptom Scales - Insomnia | -9.18 ± 3.955 | -9.50 ± 7.090 |
| Symptom Scales - Appetite loss | -3.76 ± 3.357 | 4.19 ± 7.009 |
| Symptom Scales - Constipation | 2.98 ± 3.248 | 1.19 ± 8.129 |
| Symptom Scales - Diarrhoea | 0.31 ± 3.711 | 1.68 ± 8.204 |
| Symptom Scales - Financial difficulties | -6.82 ± 3.853 | 0.58 ± 6.297 |
Subjects who withdrew during the RCP before Week 16 will have their number of units of PRBC estimated from the duration they were in the study.
| PRBC units | Pegcetacoplan to Pegcetacoplan | Eculizumab to Pegcetacoplan |
|---|---|---|
| Total Number of PRBC Units Transfused During the RCP | 26 | 198 |
Baseline was the average of measurements recorded before taking the first dose of pegcetacoplan, which included local and central laboratory values during the screening period. Analysis excluded data before the RCP and was censored for transfusions.
| g/dL | Pegcetacoplan to Pegcetacoplan | Eculizumab to Pegcetacoplan |
|---|---|---|
| Mean Change From Baseline to Week 48 in Hb Level During the Treatment Period | 2.47 ± 1.72 | 2.93 ± 2.09 |
Baseline was the average of measurements recorded before taking the first dose of pegcetacoplan, which included local and central laboratory values during the screening period. Analysis excluded data before the RCP and was censored for transfusions.
| g/dL | Open-label Period: Continue Pegcetacoplan | Open-label Period: Crossover to Pegcetacoplan |
|---|---|---|
| Mean Change From Week 17 to Week 48 in Hb Level During the Open-label Period | -0.16 ± 1.154 | 2.89 ± 2.078 |
Baseline was the average of available measurements recorded from central laboratory before taking the first dose of pegcetacoplan. Analysis excluded data before the RCP and was censored for transfusions.
| 10^9 cells/L | Pegcetacoplan to Pegcetacoplan | Eculizumab to Pegcetacoplan |
|---|---|---|
| Mean Change From Baseline to Week 48 in ARC During the Treatment Period | -135.64 ± 67.90 | -128.22 ± 59.60 |
Baseline was the average of available measurements recorded from central laboratory before taking the first dose of pegcetacoplan. Analysis excluded data before the RCP and was censored for transfusions.
| 10^9 cells/L | Open-label Period: Continue Pegcetacoplan | Open-label Period: Crossover to Pegcetacoplan |
|---|---|---|
| Mean Change From Week 17 to Week 48 in ARC During the Open-label Period | -6.50 ± 26.471 | -121.15 ± 70.969 |
Baseline was the average of available measurements recorded from central laboratory before taking the first dose of pegcetacoplan. Analysis excluded data before the RCP and was censored for transfusions.
| U/L | Pegcetacoplan to Pegcetacoplan | Eculizumab to Pegcetacoplan |
|---|---|---|
| Mean Change From Baseline to Week 48 in LDH Level During the Treatment Period | -41.53 ± 153.68 | -105.27 ± 315.59 |
Baseline was the average of available measurements recorded from central laboratory before taking the first dose of pegcetacoplan. Analysis excluded data before the RCP and was censored for transfusions.
| U/L | Open-label Period: Continue Pegcetacoplan | Open-label Period: Crossover to Pegcetacoplan |
|---|---|---|
| Mean Change From Week 17 to Week 48 in LDH Level During the Open-label Period | 8.03 ± 129.285 | -46.84 ± 292.607 |
The FACIT-fatigue scale version 4 is a 13-item Likert scaled instrument where the subject was presented with 13 statements and asked to indicate their response as it applied to the past 7 days. The 5 possible responses were 'Not at all' (0), 'A little bit (1), 'Somewhat' (2), 'Quite a bit' (3) and 'Very much' (4). With 13 statements the total score had a range of 0 to 52. A higher score corresponds to a higher QoL. Baseline was the last available, nonmissing observation before taking the first dose of pegcetacoplan. Data collected after transfusion is excluded from analysis.
| Score on a scale | Pegcetacoplan to Pegcetacoplan | Eculizumab to Pegcetacoplan |
|---|---|---|
| Mean Change From Baseline to Week 48 in FACIT-Fatigue Scale Score During the Treatment Period | 10.14 ± 9.06 | 9.62 ± 10.34 |
The FACIT-fatigue scale is a 13 item Likert scaled instrument where the subject was presented with 13 statements and asked to indicate their response as it applied to the past 7 days. The 5 possible responses were 'Not at all' (0), 'A little bit (1), 'Somewhat' (2), 'Quite a bit' (3) and 'Very much' (4). With 13 statements the total score had a range of 0 to 52. Higher score corresponds to a higher QoL.
| Score on a scale | Open-label Period: Continue Pegcetacoplan | Open-label Period: Crossover to Pegcetacoplan |
|---|---|---|
| Mean Change From Week 17 to Week 48 in FACIT-Fatigue Scale Score During the Open-label Period | 1.28 ± 7.805 | 10.19 ± 10.973 |
The LASA consists of 3 items, where the respondents were asked to rate their perceived level of functioning. Specific domains included activity level, ability to carry out daily activities, and an item for overall QoL. Their level of functioning was reported on a 0 to 100 scale with 0 indicates "As low as could be" and 100 indicates "As high as could be". The combined score ranged from 0 to 300, with higher scores corresponding to a higher QoL.
| Score on a scale | Pegcetacoplan to Pegcetacoplan | Eculizumab to Pegcetacoplan |
|---|---|---|
| Mean Change From Baseline to Week 48 in LASA Scores During the Treatment Period | 58.66 ± 51.16 | 56.52 ± 65.55 |
The FACIT-fatigue scale is a 13 item Likert scaled instrument where the subject was presented with 13 statements and asked to indicate their response as it applied to the past 7 days. The 5 possible responses were 'Not at all' (0), 'A little bit (1), 'Somewhat' (2), 'Quite a bit' (3) and 'Very much' (4). With 13 statements the total score had a range of 0 to 52. Higher score corresponds to a higher QoL.
| Score on a scale | Open-label Period: Continue Pegcetacoplan | Open-label Period: Crossover to Pegcetacoplan |
|---|---|---|
| Mean Change From Week 17 to Week 48 in LASA Scores During the Open-label Period | 13.13 ± 46.296 | 62.92 ± 60.053 |
The EORTC QLQ-C30 questionnaire (version 3.0) consists of 30 questions comprised of both multi-item scales and single-item measures to assess overall QoL in subjects. Questions are designated by functional scales, symptom scales, and global subject QoL/overall perceived health status. For the first 28 questions the 4 possible responses are 'Not at all' (1), 'A little' (2), 'Quite a bit' (3) and 'Very much' (4). For the remaining 2 questions the response is requested on a 7-point scale from 1 ('Very poor') to 7 ('Excellent'). The raw scale scores were linear transformed, producing scale scores that ranged from 0% to 100%. A high scale score represents a higher response level. Hence for the functional scales and the global health status a higher score indicates a better QoL, whilst for the symptom scale scores this is implied by a lower score.
| Score on a scale | Pegcetacoplan to Pegcetacoplan | Eculizumab to Pegcetacoplan |
|---|---|---|
| Global Health Status/QoL | 18.89 ± 17.635 | 13.99 ± 22.912 |
| Functional Scales - Physical functioning | 15.33 ± 15.278 | 10.80 ± 17.765 |
| Functional Scales - Role functioning | 16.67 ± 27.334 | 20.11 ± 27.595 |
| Functional Scales - Emotional functioning | 10.28 ± 18.657 | 5.36 ± 17.005 |
| Functional Scales - Cognitive functioning | 7.78 ± 23.462 | 0.00 ± 18.703 |
| Functional Scales - Social functioning | 16.11 ± 24.166 | 14.88 ± 22.379 |
| Symptom Scales - Fatigue | -21.48 ± 26.733 | -23.75 ± 29.506 |
| Symptom Scales - Nausea and vomiting | -2.22 ± 11.357 | 0.00 ± 4.454 |
| Symptom Scales - Pain | 0.56 ± 27.849 | 3.45 ± 20.596 |
| Symptom Scales - Dyspnoea | -17.78 ± 29.985 | -27.59 ± 33.415 |
| Symptom Scales - Insomnia | -6.67 ± 25.371 | 0.00 ± 28.172 |
| Symptom Scales - Appetite loss | -7.78 ± 14.339 | -3.45 ± 22.440 |
| Symptom Scales - Constipation | -1.11 ± 22.289 | -2.38 ± 8.742 |
| Symptom Scales - Diarrhoea | 1.11 ± 29.664 | 5.95 ± 15.853 |
| Symptom Scales - Financial difficulties | -15.56 ± 24.343 | -8.33 ± 19.510 |
The EORTC QLQ-C30 questionnaire (version 3.0) consists of 30 questions comprised of both multi-item scales and single-item measures to assess overall QoL in subjects. Questions are designated by functional scales, symptom scales, and global subject QoL/overall perceived health status. For the first 28 questions the 4 possible responses are 'Not at all' (1), 'A little' (2), 'Quite a bit' (3) and 'Very much' (4). For the remaining 2 questions the response is requested on a 7-point scale from 1 ('Very poor') to 7 ('Excellent'). The raw scale scores were linear transformed, producing scale scores that ranged from 0% to 100%. A high scale score represents a higher response level. Hence for the functional scales and the global health status a higher score indicates a better QoL, whilst for the symptom scale scores this is implied by a lower score.
| Score on a scale | Open-label Period: Continue Pegcetacoplan | Open-label Period: Crossover to Pegcetacoplan |
|---|---|---|
| Global Health Status/QoL | 7.22 ± 19.664 | 23.08 ± 22.149 |
| Functional Scales - Physical functioning | 0.89 ± 10.168 | 11.03 ± 17.173 |
| Functional Scales - Role functioning | 5.00 ± 20.599 | 19.87 ± 22.617 |
| Functional Scales - Emotional functioning | -2.22 ± 27.328 | 1.92 ± 13.806 |
| Functional Scales - Cognitive functioning | -2.78 ± 16.999 | 2.56 ± 24.355 |
| Functional Scales - Social functioning | 3.89 ± 18.919 | 12.18 ± 23.361 |
| Symptom Scales - Fatigue | -2.96 ± 20.824 | -23.08 ± 28.790 |
| Symptom Scales - Nausea and vomiting | -2.22 ± 5.762 | -4.49 ± 12.072 |
| Symptom Scales - Pain | -2.78 ± 23.195 | -5.77 ± 21.051 |
| Symptom Scales - Dyspnoea | 3.33 ± 25.295 | -19.23 ± 28.555 |
| Symptom Scales - Insomnia | 8.89 ± 23.050 | -5.13 ± 27.797 |
| Symptom Scales - Appetite loss | -8.89 ± 26.164 | -5.13 ± 22.494 |
| Symptom Scales - Constipation | -1.11 ± 20.498 | -1.28 ± 11.473 |
| Symptom Scales - Diarrhoea | -4.44 ± 28.679 | 3.85 ± 27.206 |
| Symptom Scales - Financial difficulties | -2.22 ± 12.172 | -2.56 ± 16.119 |
Number of units of PRBC transfused to subjects in the open-label period are reported.
| PRBC Units | Open-label Period: Continue Pegcetacoplan | Open-label Period: Crossover to Pegcetacoplan | Open-label Run-in Period: Crossover to Pegcetacoplan |
|---|---|---|---|
| Total Number of PRBC Units Transfused During the Open-Label Period | 68 | 110 | 14 |
Collected over Day -28 to Week 54, a maximum of approximately 58 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Run-in Period: Pegcetacoplan + Eculizumab | 0/80 (0%) | 4/80 (5%) | 71/80 (88.8%) |
| Open-label Period: Pegcetacoplan | 1/77 (1.3%) | 18/77 (23.4%) | 71/77 (92.2%) |
| RCP: Eculizumab | 0/39 (0%) | 5/39 (12.8%) | 36/39 (92.3%) |
| RCP: Pegcetacoplan | 0/41 (0%) | 7/41 (17.1%) | 36/41 (87.8%) |
| Event | Run-in Period: Pegcetacoplan + Eculizumab | Open-label Period: Pegcetacoplan | RCP: Eculizumab | RCP: Pegcetacoplan |
|---|---|---|---|---|
| HaemolysisBlood and lymphatic system disorders | 1/80 | 5/77 | 1/39 | 2/41 |
| AnaemiaBlood and lymphatic system disorders | 0/80 | 0/77 | 2/39 | 0/41 |
| GastroenteritisInfections and infestations | 0/80 | 2/77 | 0/39 | 1/41 |
| HyperthermiaGeneral disorders | 0/80 | 0/77 | 1/39 | 0/41 |
| Haemolytic anaemiaBlood and lymphatic system disorders | 0/80 | 1/77 | 1/39 | 0/41 |
| Abdominal painGastrointestinal disorders | 0/80 | 1/77 | 1/39 | 0/41 |
| Hepatocellular injuryHepatobiliary disorders | 0/80 | 0/77 | 1/39 | 0/41 |
| HyperbilirubinaemiaHepatobiliary disorders | 0/80 | 0/77 | 1/39 | 0/41 |
| JaundiceHepatobiliary disorders | 0/80 | 0/77 | 1/39 | 0/41 |
| SepsisInfections and infestations | 2/80 | 1/77 | 0/39 | 0/41 |
| Event | Run-in Period: Pegcetacoplan + Eculizumab | Open-label Period: Pegcetacoplan | RCP: Eculizumab | RCP: Pegcetacoplan |
|---|---|---|---|---|
| Injection site erythemaGeneral disorders | 33/80 | 9/77 | 0/39 | 7/41 |
| HaemolysisBlood and lymphatic system disorders | 1/80 | 13/77 | 9/39 | 4/41 |
| HeadacheNervous system disorders | 10/80 | 8/77 | 9/39 | 2/41 |
| DiarrhoeaGastrointestinal disorders | 10/80 | 11/77 | 2/39 | 9/41 |
| NasopharyngitisInfections and infestations | 4/80 | 12/77 | 2/39 | 3/41 |
| FatigueGeneral disorders | 5/80 | 8/77 | 6/39 | 2/41 |
| Injection site pruritusGeneral disorders | 12/80 | 5/77 | 0/39 | 1/41 |
| AstheniaGeneral disorders | 1/80 | 4/77 | 5/39 | 3/41 |
| AnaemiaBlood and lymphatic system disorders | 1/80 | 2/77 | 5/39 | 0/41 |
| DizzinessNervous system disorders | 3/80 | 3/77 | 5/39 | 1/41 |
The intent-to-treat (ITT) set included all randomized subjects.
| Age, Categorical(Participants) | Pegcetacoplan to Pegcetacoplan | Eculizumab to Pegcetacoplan | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 31 | 32 | 63 |
| >=65 years | 10 | 7 | 17 |
| Sex: Female, Male(Participants) | Pegcetacoplan to Pegcetacoplan | Eculizumab to Pegcetacoplan | Total |
|---|---|---|---|
| Female | 27 | 22 | 49 |
| Male | 14 | 17 | 31 |
| Ethnicity (NIH/OMB)(Participants) | Pegcetacoplan to Pegcetacoplan | Eculizumab to Pegcetacoplan | Total |
|---|---|---|---|
| Hispanic or Latino | 2 | 1 | 3 |
| Not Hispanic or Latino | 29 | 32 | 61 |
| Unknown or Not Reported | 10 | 6 | 16 |
| Race/Ethnicity, Customized(Participants) | Pegcetacoplan to Pegcetacoplan | Eculizumab to Pegcetacoplan | Total |
|---|---|---|---|
| Asian | 5 | 7 | 12 |
| Black or African American | 2 | 0 | 2 |
| White | 24 | 25 | 49 |
| Other | 0 | 1 | 1 |
| Not Reported | 10 | 6 | 16 |
| Number of transfusions in the last 12 months prior to Day -28(Participants) | Pegcetacoplan to Pegcetacoplan | Eculizumab to Pegcetacoplan | Total |
|---|---|---|---|
| < 4 | 20 | 16 | 36 |
| ≥ 4 | 21 | 23 | 44 |
| Platelet count at screening(Participants) | Pegcetacoplan to Pegcetacoplan | Eculizumab to Pegcetacoplan | Total |
|---|---|---|---|
| <100,000 (count/mm^3) | 12 | 9 | 21 |
| ≥100,000 (count/mm^3) | 29 | 30 | 59 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Jun 2018 to primary completion in Nov 2019, 17 months.
Results were first posted in Mar 2022, 2 years 4 months after primary completion. A results delay was requested in Jul 2020.
Of 35 industry-sponsored phase 3 interventional studies under Hemoglobinuria, Paroxysmal, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 41. This study's 17 months is below that.
Counting every sponsor, half of 35 studies reached it within 23 months; a quarter within 15 and three quarters within 41.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Pegcetacoplan
Apellis Pharmaceuticals, Inc. →